Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
ROCK, rho-associated coiled-coil containing protein kinase
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Future research must navigate the complexity of glial states to precisely target disease-relevant glial subtypes while preserving physiological functions
Dihexa mimics HGF and activates the c-Met receptor directly
